Skip to content

Search Results

No Matching Results

    Recently Viewed

      Listening...

      HomeOur CompanyDiscover J&JOffice of the Chief Medical Officer

      Office of the Chief Medical Officer

      The Johnson & Johnson Office of the Chief Medical Officer (OCMO) is a global, functionally independent group of medical and scientific professionals working across Johnson & Johnson to guide excellence in product safety and development. We apply our expertise in safety science, epidemiology, and bioethics to inform evidence- and science-based product decisions that put people first. The OCMO also chairs the Pharmaceutical Development Committee, which reviews product development plans to ensure that our products address unmet needs and benefit the people who will ultimately use them.

      Johnson & Johnson Chief
      Medical Officers

      Our Chief Medical Officers drive medical safety excellence and innovation across Johnson & Johnson.
      • William N. (Bill) Hait is Executive Vice President, Chief External Innovation and Medical Officer, and a member of the Johnson & Johnson Executive Committee. In this role Bill is responsible for leading external sourcing and creation of transformational innovation to help Johnson & Johnson achieve its mission to improve human health. He also oversees the Research and Development Management Committee that focuses on talent development and best-practice sharing within the Company’s R&D community, as well as Company efforts to advance mental health, improve healthcare for the world’s most vulnerable and underserved populations, and meet its obligations around product safety and ethical research, aligned with Our Credo.
      • Aran is the Chief Medical Officer for Johnson & Johnson Innovative Medicine, the pharmaceuticals segment of the Company, which applies rigorous science and compassion to address the most complex diseases of our time and unlock the potential medicines of tomorrow.
      • Jijo is the Chief Medical Officer for Johnson & Johnson MedTech & External Innovation. In the role, he is responsible for overseeing patient monitoring and safety surveillance practices and co-chairing the respective R&D Development Pipeline Review Committees. Jijo is a member of the Johnson & Johnson Office of the Chief Medical Officer Senior Leadership Team and the MedTech R&D Leadership Team. Previously, Jijo was the Chief Medical Officer for the Johnson & Johnson Family of Consumer Companies where he led the Safety Council for the Consumer sector and was a member of the Consumer R&D Leadership Team. He currently serves as the Chair of the Board of Directors of the Medical Device Innovation Consortium (MDIC) to advance medical device regulatory science and bring innovative, safe and effective life-changing devices to those who need it most.

      Delivering medical safety excellence that puts people first

      Driven by the needs of the people who use our products, our focus is to provide safe products for the people who use them.

      Driving excellence in safety at Johnson & Johnson

      A Q&A with Gary Eichenbaum, Ph.D., Vice President, Translational Science and Safety, Office of the Chief Medical Officer, Johnson & Johnson

      Decisions through real-world data

      We are leading the way in new approaches for generating high-quality and reliable real-world evidence to inform important product decisions.

      What is real-world evidence and how does it help patients?

      As Johnson & Johnson’s Vice President and Global Head of Epidemiology, Josh Gagne and his team study real-world data to further understand the safety and effectiveness of our products across many different kinds of patients and clinical environments to help inform important decisions that ultimately improve care for patients

      Ethical scientific practices & policies

      We champion bioethical principles to guide scientific innovation and collaborate to advance people-centric product development and responsible data sharing practices.

      How Johnson & Johnson is helping patients through its compassionate use program

      The company’s mission is to care for the world—one person at a time. Learn how Johnson & Johnson is leading the charge to improve the process by which very sick patients may apply for access to investigational medications.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.